Novo Nordisk sued competitor Eli Lilly on Tuesday, alleging the drugmaker engaged in false advertising by claiming its GLP-1 drugs are superior to Novo’s. The lawsuit accuses Eli Lilly of misleading consumers by using outdated clinical trial data to make Zepbound and Mounjaro appear more effective than Novo’s drugs, Wegovy and Ozempic, for weight loss … Read more
IE 11 is not supported. For an optimal experience visit our site on another browser. Now Playing Novo Nordisk Sues Eli Lilly Over Weight Loss Drug Advertisement 02:08 UP NEXT Hundreds Gather to Honor Nolan Wells at His Funeral 02:29 Spain Celebrates FIFA World Cup Win With Huge Victory Parade 02:30 Exclusive: Discovery Channel Finds … Read more
Novo Nordisk, the pharmaceutical company behind Ozempic, has received a warning letter from the U.S. Food and Drug Administration over issues with its procedures for reporting potential side effects of the flagship diabetes drug, which is also prescribed for weight loss. In the letter, dated March 5, the FDA cited three deaths among patients receiving … Read more
Novo Nordisk said Tuesday it will slash its prices for Wegovy and Ozempic beginning next year by up to 50%, highlighting the growing competition among pharmaceutical firms for customers seeking weight-loss drugs. The Danish drugmaker said it plans to offer the medicines for $675 per month starting in January 2027, representing a 50% reduction in … Read more
Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting next year, the Danish drugmaker said on Tuesday. The price cuts will be effective January 1 next year, coinciding with the implementation of new, lower prices for the same drugs under federal Medicare … Read more